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Abstract
Background: The incidence of Alzheimer’s disease (AD) strongly relates to advanced age and progressive deposition
of cerebral amyloid-beta (Aβ), hyperphosphorylated tau, and iron. The purpose of this study was to investigate the
relationship between cerebral dynamic functional connectivity and variability of long-term cognitive performance in
healthy, elderly subjects, allowing for local pathology and genetic risk.
Methods: Thirty seven participants (mean (SD) age 74 (6.0) years, Mini-Mental State Examination 29.0 (1.2)) were
dichotomized based on repeated neuropsychological test performance within 2 years. Cerebral Aβ was measured by
11C Pittsburgh Compound-B positron emission tomography, and iron by quantitative susceptibility mapping magnetic
resonance imaging (MRI) at an ultra-high field strength of 7 Tesla (7T). Dynamic functional connectivity patterns were
investigated by resting-state functional MRI at 7T and tested for interactive effects with genetic AD risk (apolipoprotein
E (ApoE)-ε4 carrier status).
Results: A relationship between low episodic memory and a lower expression of anterior-posterior connectivity was
seen (F(9,27) = 3.23, p < 0.008), moderated by ApoE-ε4 (F(9,27) = 2.22, p < 0.005). Inherent node-strength was related to
local iron (F(5,30) = 13.2; p < 0.022).
Conclusion: Our data indicate that altered dynamic anterior-posterior brain connectivity is a characteristic of low
memory performance in the subclinical range and genetic risk for AD in the elderly. As the observed altered brain
network properties are associated with increased local iron, our findings may reflect secondary neuronal changes due
to pathologic processes including oxidative stress.
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Background
Sporadic Alzheimer’s disease (AD) is the most frequent
cause of dementia [1] and is characterized pathologically
by deposition of amyloid-beta (Aβ), hyperphosphorylated
tau, and progressive neuronal dysfunction [2, 3]. Patho-
logical brain change in AD furthermore includes the
increased accumulation of cerebral iron, which has been
linked to several pathological processes associated with
risk for AD and disease progression [4–9].
Clinically, AD develops gradually and presents with pro-
gressive decline in multiple cognitive domains, particularly
affecting episodic memory, executive functioning, and per-
ceptual speed [10–13]. While these alterations may also
take place during normal aging, the concurrent incidence
of subtle cognitive dysfunction and emerging AD brain
pathology in the cognitively normal elderly is considered
to reflect a preclinical stage of AD [14, 15]. Moreover,
progression of AD is significantly affected by genetic pre-
disposition and presence of the apolipoprotein E (ApoE)
ε4 allele, which is the strongest known genetic risk factor
for late-onset AD [16–20].
A variety of noninvasive neuroimaging techniques have
been developed to assess AD pathology directly and AD-
associated neurobiological changes. Positron emission
tomography (PET) using the 11C-labeled tracer Pittsburgh
Compound-B (PiB), is a validated method for measuring
fibrillar Aβ [21, 22] and has been used to assess patho-
logical burden in several clinical studies [23–25].
Cerebral iron can be measured in vivo by applying
quantitative susceptibility mapping (QSM) magnetic res-
onance imaging (MRI) [26, 27], which has very high
signal-to-noise ratios (SNRs) when acquired at ultra-
high field strength [28, 29].
While the blood-oxygen-level dependent (BOLD)
functional MRI (fMRI) contrast reflects in vivo neuronal
activity [30, 31], an ultra-high field strength of 7 Tesla
(7T) may provide enhanced SNR and enriched contrast
[32–35]. Therefore, for the current study, a three-
dimensional T2-weighted BOLD fMRI sequence was
used (“T2-prep fMRI”), which was specifically designed
for ultra-high magnetic field strength MRI acquisition
[36]. Functional connectivity, as inferred from synchron-
ous fluctuations in activity in spatially distant brain areas
[37], is an established measure for investigating the in-
tegrity of functional brain networks and their potential
impairment in AD [38–41]. Investigation of “dynamic
functional connectivity” additionally provides informa-
tion on the expression of brain networks over time
and has been used to characterize changes in brain
network connectivity in neuropsychiatric disorders
earlier [42–45].
The primary aim of this study was to investigate whether
dynamic expression of cognitive brain networks relates to
interindividual variation of cognitive performance in
healthy elderly subjects and their genetic predisposition
for AD. Considering that “stationary” connectivity is sig-
nificantly affected by local neurodegenerative brain change
[46–50], the second aim of this study was to examine the
relationship between dynamic network expression and
neuropathology. 11C-PiB-PET and QSM-MRI were thus
used for measuring neuropathological burden, as indicated
by the accumulation of cerebral Aβ and iron. QSM-MRI
and resting state T2-prep fMRI were performed at an
ultra-high field strength of 7T. Interindividual variability of
cognitive performance over time was assessed by perform-
ing two neuropsychological tests for each participant,
2 years apart.
Methods
Study population
The study sample included 37 (13 females and 24 males)
cognitively normal Swiss-German elderly adults (mean
age (SD) 73 (6.6) years, range 62–89 years, mean educa-
tion (SD) 14 (3) years, range 8–20) living in the canton
Zurich from an ongoing study [51], who received ultra-
high field strength MRI at 7T and neuropsychological
follow-up after 2 years (Table 1). Genotyping of the
APOE gene (rs429358 and rs7412) revealed 13 carriers
Table 1 Mean scores of neuropsychological tests at inclusion of study and follow-up, as well as changes (%) in performance
between sessions
Test Inclusion Follow-up p value* Total sample (n = 37),
% change per year
No decline, %
change per year
No decline
p value*
Decline, % change
per year
Decline p value*
MMSE 29.03 (1.17) 29.03 (1.19) 1.00 0.00 1.83% (n = 23) <0.001 –1.97% (n = 14) <0.0001
BNT 14.32 (1) 14.46 (0.84) 0.53 0.01 1.45% (n = 33) <0.01 –5.53% (n = 4) <0.015
DSF 6.81 (1.66) 6.84 (1.55) 0.94 0.02 10.32% (n = 24) <0.01 –14.09% (n = 13) <0.001
DSB 6.08 (1.57) 5.95 (1.73) 0.73 0.00 10.32% (n = 20) <0.001 –11.69% (n = 17) <0.0001
TMT B/A 2.83 (1.27) 2.61 (1) 0.41 0.00 17.51% (n = 19) <0.002 –18.84% (n = 18) <0.001
VLMT delayed recall 8.49 (3.92) 9.62 (4.21) 0.23 0.19 46.22% (n = 19) <0.001 –9.31% (n = 18) <0.01
Values are shown as mean (SD)
*Follow-up versus inclusion
BNT Boston Naming Test, DSB Digit Span Backward, DSF Digit Span Forward, MMSE Mini-Mental State Examination, TMT B/A Trail Making Test part B/part A, VLMT
Verbal Learning and Memory Test
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with at least one ApoE-ε4 allele (two subjects had the
genotype ε4/ε4). All study procedures were carried out
in concordance with regulations issued by the local
ethics authority (Kantonale Ethikkommission Zürich,
www.kek.zh.ch), as well as good clinical practice (GCP)
guidelines and the declaration of Helsinki [52]. Written
informed consent was obtained from all participants be-
fore inclusion in the study. Inclusion criteria were age
between 55 and 80 years, no significant cognitive impair-
ment as indicated by Mini-Mental State Examination
(MMSE) <26, no acute medical or neurological comor-
bidities, and no present psychiatric disorder or current
substance abuse. Exclusion criteria included evidence of
infarction and focal or significant hemorrhagic lesions in
the MRI, as indicated in detail previously for neuroimag-
ing studies on nondemented elderly populations at our
center [8, 41, 51, 53].
Cognitive assessment of participants
All subjects were evaluated by neuropsychological tests
as described previously [51]. For the current study,
neuropsychological follow-up was scheduled after 2 years
and included German language versions of the MMSE
as a general measure of cognitive performance [54], as
well as domain-specific testing using the Digit Span
Forward (DSF) and Digit Span Backward (DSB) for
measuring working memory [55], the delayed recall
Verbal Learning and Memory Test (VLMT) [56] for
assessing episodic memory, the abbreviated CERAD
Boston Naming Test (BNT) on confrontational word re-
trieval [57, 58], and the ratio between part B and A of
the Trail Making Test (TMT) as a measure of executive
function [59]. To characterize the performance of each
measure over time, the percentage difference between
follow-up value and baseline was used to obtain yearly
variability ratios (relative change per 365 days) for each
participant and each investigated cognitive domain.
Subjects were allocated to the group “Decline” if the re-
spective yearly variability ratios were negative and to the
group “No Decline” if ratios were equal or better than at
inclusion (Table 1).
Acquisition of MRI data
Participants underwent one session of scanning using a Phi-
lips 7-Tesla Achieva whole-body scanner (Philips Health-
care, Best, The Netherlands) equipped with a Nova Medical
quadrature transmit head coil and 32-channel receive coil
array, located at the Swiss Federal Institute of Technology
(ETH) in Zurich, as reported previously [8, 41, 53]. For the
current study, this scanner was used to acquire T1-
weighted MP2RAGE image [60] data (TR/TE = 4.8 ms/
2.1 ms, voxel size = 0.6 × 0.6 × 0.6 mm3, SENSE-factor = 2 ×
1 × 2, scan duration = 7:50 min) for referencing and auto-
mated image segmentation. Resting-state fMRI data was
acquired using a 3D T2-prep gradient recalled echo (GRE)
sequence, optimized for ultra-high field strength acquisition
[36] (TR = 2 s, TRGRE/TEGRE = 3.08 ms/1.6 ms, voxel size =
1.5 × 1.5 × 1.5 mm3, scan duration = 7:03 min). Iron load
was measured by QSM-MRI at ultra-high field strength
using a multi-echo three-dimensional gradient recalled echo
(GRE) sequence with three echoes (TR/TE/ΔTE= 23/6/
6 ms, flip angle = 10°, voxel size = 0.5 × 0.5 × 0.5 mm3,
SENSE-factor = 2.5 × 1 × 2, flow-compensated, scan dur-
ation = 13:48 min) for acquiring anatomical MR measures
of magnitude and phase for calculation of QSM images
using a previously described pipeline [8, 29].
Acquisition of PET data
Cerebral Aβ was measured with 11C-PiB-PET [8, 41, 53].
Briefly, participants were administered a dose of 350 MBq
of the 11C-labeled tracer intravenously and cerebral amyl-
oid deposition was estimated based on late frame signals
representing 50–70 min. Measures of individual brain Aβ
load were derived from the ratio of standardized uptake
values (SUV) of regional PiB referenced to cerebellar SUV
after coregistration using the PMOD brain tool (PNEURO)
software, Version 3.4 (PMOD Technologies Ltd., Zurich,
Switzerland).
Processing of fMRI data
Structural and functional images were preprocessed with
a standardized in-house-developed preprocessing pipeline
[61] implemented in MATLAB scripts (MATLAB 2015b,
Version 8.6; MathWorks Inc., Natick, MA, USA), which
included functions from SPM8, SPM12 (http://www.fil.io-
n.ucl.ac.uk/spm/) and DPARSFA toolboxes [62]. Images
were spatially realigned and smoothed (FWHM= 5 mm).
Nuisance variables were regressed out from the regional
time series (these included linear and quadratic trends, six
head motion parameters, average cerebrospinal fluid sig-
nal from ventricular masks and white matter signal from
white matter masks). All the functional data was postpro-
cessed using the Artifact Detection Tool (ART; www.nitr-
c.org/projects/artifact_detect/), resulting in exclusion of
three subjects from further analysis due to excess motion
(>2 mm). The remaining 37 functional volumes were re-
gionally parcellated using the automated anatomical label-
ing (AAL) atlas [63], resulting in the definition of 90
anatomical grey-matter regions of interest. Regional mean
time series were then extracted by averaging the prepro-
cessed BOLD signal over all voxels in each region and fil-
tered with a band-pass filter cutoff (0.017–0.15 Hz), as
performed previously for investigating dynamic functional
networks at rest [45].
Assessment of dynamic functional connectivity
A whole brain dynamic functional connectivity (FC)
matrix for each subject was calculated using a sliding time
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window approach (window size = 30 TRs = 60 s; step =1
TR = 2s) to calculate the time-varying correlations
between BOLD fluctuations in distinct brain regions, as
reported previously [45, 64]. Briefly, in order to account
for spurious fluctuations while preserving meaningful fluc-
tuations within the time windows, the window size was
determined by calculating 1/smallest frequency in the
data, represented by the high-pass filter cutoff [64]. The
FC matrices obtained for all windows were then vector-
ized and temporally concatenated to obtain a dFC (con-
nections × time) matrix, which was normalized by first
removing the global mean and dividing for the global
standard deviation and secondly applying a row-wise
demeaning to focus on the exclusive contributions of
dynamics. Finally, dFC data were concatenated into a
(connections × time*subjects) matrix and principal com-
ponent analysis (PCA) was used for reducing data dimen-
sionality and to define subject specific eigenconnectivities,
referring to distinct connectivity patterns [45] (i.e., build-
ing blocks of dFC, highlighting dominant patterns of FC
increase/decrease that recur across time and in the popu-
lation). For the current study, the following properties of
dynamic network connectivity were investigated: 1) Time-
contributed weights and percentage of positive weights
were obtained for identified connectivity patterns as a
measure of dynamic FC changes and compared between
groups for inferring expression of connectivity patterns
within the acquired fMRI data (“network expression”).
Effects of cognitive decline and ApoE-ε4 status on
changes in dynamic FC network expression were assessed
using a multivariate Hotelling’s T2 test. Singular value de-
composition with bootstrapping matched to a Procrustes
transform [65] was conducted to test the reproducibility
of the eigenconnectivity patterns [66]. Through this
process, the stronger connections are attributed higher
values and the weaker connections are gradually dis-
carded. This eases interpretation without affecting group
comparison tests and these data were therefore used for
the visualization of the eigenconnectivity networks. 2.)
Node strengths for significant connectivity patterns were
calculated as a graph theoretical measure indicating in-
volvement of a particular region in a network, as derived
from the sum of all connection weights for all connections
attached to a given node [67].
Statistical analysis
All data processing was performed in MATLAB (2015b,
Version 8.6) and its Statistics and Machine Learning Tool-
box (Version 10.0). A Hotelling’s T2 multivariate test in
combination with sequentially rejective Holm-Bonferroni
correction [68] for investigating variability indices pertain-
ing to six neuropsychological tests was used to assess
relationship with expression of dynamic connectivity pat-
terns. To follow-up on significant associations, secondary
analysis investigated: 1) interactive effects of test perform-
ance and ApoE-ε4 on network alterations using a multi-
variate Hotelling’s T2 test; and 2) relationships between
node strength of significant connectivity patterns and local
Aβ and iron load, respectively, by applying false discovery
rate (FDR)-corrected permutation-based multivariate
analysis of variance (MANOVA) [69]. Effect sizes of differ-
ences between the “Decline” and “No decline” groups were
estimated using Cohen’s d [70].
Results
Stratification of the study sample by identification of
participants with lower cognitive performance after
2 years
Participants were neuropsychologically tested at baseline
and after 2 years (mean (SD) follow-up time between
testing, 719 (277) days). All participants had normal
levels of general cognitive performance both at inclusion
(mean (SD) MMSE 29.03 (1.17)), as well as at follow-up
(mean (SD) MMSE 29.03 (1.19), mean average change
per year 0.39%) and for the entire population (n = 37) no
significant difference between baseline and follow-up
could be observed for the investigated neuropsycho-
logical tests. For stratifying the study population by
cognitive performance over time, a subgroup of “de-
cliners” was defined that included subjects with negative
yearly variability ratios for each cognitive domain.
Decliners thus included four subjects for the Boston
Naming Test (average yearly change –5.53%), 13 subjects
for the Digit Span Forward Test (average yearly change
–14.09%), 17 subjects for the Digit Span Backward Test
(average yearly change –11.69%), 18 subjects for Trail-
Making Test ratio (average yearly change –18.84%), and
18 subjects for the VLMT delayed recall test (average
yearly change –9.31%) (Table 1). By generating a Venn
diagram, a small degree of overlap between decline in
the respective domains could be visualized (Fig. 1), indi-
cating no participant with concurrent decline in all five
tests and only two subjects with declined performance
in four out of five tests. Moreover, the null hypothesis
that the performed tests for domain performance
assessed one common factor was dismissed by means of
a factor analysis (χ2(5) = 11.995, p < 0.04).
Lower expression of an anterior-posterior network in
subjects with declined episodic memory performance
Individuals characterized as having memory decline showed
reduced expression of an anterior-posterior connectivity
pattern, which remained significant (alpha = 5%) after ap-
plying Holm-Bonferroni correction for multiple testing
(Roy’s maximum root F(9,27) = 3.23, p < 0.0078; factor load-
ing –0.521; Fig. 2a and b). No significant effects (Roy’s max-
imum root test, indicated are uncorrected p values without
adjustment for multiple testing) on dynamic FC were found
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Fig. 1 Venn diagram illustrating the relationship of “decliners” among the different strata. Each circle is labeled according to the neuropsychological
test it represents: A, delayed recall Verbal Learning and Memory Test; B, Digit Span Backward test; C, Trail-Making Test; D, Digit Span Forward test; E,
Boston Naming Test). The small circle without a label in the same color as E also illustrates decliners in the Boston Naming Test
Fig. 2 a Coronal, sagittal and axial views of the 2% strongest connections in brain space of the anterior-posterior network. Brain regions are
shown as spheres where their size represents their degree and color represents the algebraic sign of relative node strength (red for positive, blue
for negative). Connections follow the same color scheme. b Corresponding eigenconnectivity for anterior-posterior network. Plot follows an identical
color scheme as the glass brains. Each number on the x and y axes represents a label on the AAL atlas
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for groups defined by the cognitive tests Boston Naming
(F(9,27) = 0.53, p = 0.85), Digit Span Forward (F(9,27) =
1.33, p = 0.27), Digit Span Backward (F(9,27) = 0.97, p =
0.48) and Trail Making Test B/A (F(9,27) = 0.84, p = 0.6).
Node strength is associated with higher regional iron, but
not amyloid-beta
The observed relationship between memory decline and
anterior-posterior network expression was followed up
for potential relationships between node strength of
significant connectivity patterns and neuropathology, by
permutation MANOVA. This approach yielded a set of
five nodes where nodal contributions to the network
were associated with significantly higher susceptibility, as
an indicator of local iron, in subjects with lower memory
performance at follow-up, compared to those with equal
or better performance (F(1,35) = 13.1, p < 0.022, FDR-
corrected; Fig. 3c). The most distinct increases for local
iron were observable for the left Precuneus (Cohen’s d =
0.493), right Caudate (d = 0.410) and right anterior Cingu-
late (d = 0.160) (Fig. 4). While no significant relationship
between regional network contribution and local Aβ
load could be observed for any of the identified nodes
(p = 0.128, uncorrected), the association between node
strength in the anterior-posterior network and mem-
ory decline was not significant when correcting iron
levels for Aβ (t(27) = 12.49, p = 0.1).
Combined effects of ApoE-ε4 and declined episodic
memory performance on network expression
A multivariate Hotelling's T2 test was used to investigate
whether the observed change of dynamic connectivity in a
context of memory decline relates to the individual risk of
developing AD. Participants with both ApoE-ε4, as well as
declined memory over 2 years (n = 6), were tested against
the rest of the sample (n = 31), resulting in significant dif-
ferences in the percentage of positive weights between
groups (Roy’s maximum root F(9,27) = 2.22, p < 0.005).
Secondary testing of ApoE-ε4 carriers against noncarriers
within the group of subjects with declined memory indi-
cated a nominally significant difference in the percentage
of positive weights between groups (Roy’s maximum root
F(9,8) = 5.29, p < 0.03). Here, the factor loadings of each
eigenconnectivity point to three connectivity patterns that
drive this group difference: the global network expression
(factor loading –0.5), a fronto-temporal network (factor
loading –0.44), and a fronto-occipital network (factor load-
ing –0.48). These findings indicate a significant difference
in specific network expression associated with ApoE-ε4 car-
rier status and memory decline, concerning: 1) a pattern
showing the alteration of global connectivity (first eigen-
connectivity, positive pattern); 2) the alteration between
anterior-posterior network connectivity (negative pattern)
and interhemispheric fronto-temporal (positive pattern)
connectivity (second eigenconnectivity); and 3) the alter-
ation between parieto-temporal connections (negative pat-
tern) and fronto-occipital connectivity (positive pattern)
(Fig. 5). The negative sign of the factor loadings indicate
that these networks show an increase in the negative pat-
terns and decrease in the positive patterns.
Discussion
By implementing dynamic functional connectivity ana-
lysis on ultra-high field strength MRI at 7T, reduced ex-
pression of a dynamic anterior-posterior brain network
could be identified as a correlate of low episodic mem-
ory performance over time in cognitively normal elderly
subjects. While strength of nodes implicated in this net-
work related to mean regional susceptibility as a meas-
ure of local iron accumulation, no significant association
could be observed for local Aβ plaque density, as in-
ferred by PiB standardized uptake value ratio (SUVR).
As dynamic functional connectivity changes relates to
both lower episodic memory and ApoE-ε4, our findings
Fig. 3 a Exemplary 11C-PiB-PET image, indicating regional distribution of standardized uptake value ratio (SUVR) as a measure of local Aβ
deposition. b Exemplary QSM image at 7T, indicating regional distribution of susceptibility as used for inferring on local iron load. c Correlation
between node strength of the anterior-posterior network and local iron load. Significance as indicated by alpha of 5% after correction for multiple
testing (FDR) was reached at –log10(p) = 1.3
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may reflect brain change taking place in subjects at
increased risk for AD and preclinical stages of AD, re-
spectively. To our knowledge, this is the first study that
demonstrates a relationship between memory decline
within the normal range and altered dynamic network
connectivity as a potential correlate of increased risk for
AD in the healthy elderly.
Assessment of pathological burden included estima-
tion of Aβ plaque density by administering 11C-PiB-PET,
as has been demonstrated to be valid for characterizing
progression of AD pathology previously [21, 71–73].
Additionally, iron was measured by QSM-MRI [26, 27]
which was performed at ultra-high field strength for maxi-
mizing signal quality [28]. While functional connectivity
analysis of BOLD-fMRI data is a well-established measure
of neural integrity in AD [38, 39, 74], for the current
study, T2-prep fMRI was used to avoid signal contortion
near air cavities, but which nevertheless benefits from high
SNR at 7T [36]. Moreover, dynamic functional connectiv-
ity [42] was assessed for inferring on the temporal expres-
sion of connectivity patterns by integrating information
on both the regional extent and temporal evolution of co-
herent BOLD activity [45, 64]. The studied population was
cognitively assessed by performing tests and follow-up for
language capacity, working memory, episodic memory,
and executive function within 2 years. While neuro-
psychological assessment over time has been suggested
previously to be a particularly reliable measure of cogni-
tive performance in the elderly [75, 76], the investigated
study population in our study remained relatively stable
regarding test performance within the study period. How-
ever, by splitting the study population by algebraic sign of
yearly variability ratios, two subgroups that significantly
differed regarding their rate of decline in the investigated
cognitive domains could be identified that only showed
moderate overlap regarding cognitive domains affected by
lower performance over time. Some participants in our
study performed better at follow-up, which may be ex-
plained by practice effects as reported previously for longi-
tudinal studies on cognitively normal elderly subjects [77].
Our finding of an association between memory per-
formance and dynamic connectivity appears consistent
with a concatenation of earlier reports on altered func-
tional connectivity in AD [50, 78, 79] as well as associa-
tions between distinct cognitive impairment and increased
AD risk [15, 80]. Central nodes of the dynamic anterior-
posterior network found to be associated with episodic
memory performance exhibited increased iron for the
lower episodic memory group. The strongest effects were
observable for the left precuneus, right caudate, and right
anterior cingulate. This observation appears consistent
with previous reports on subcortical regions being primar-
ily affected by iron accumulation in neurodegenerative
brain disorders [81, 82]. While no differences in local Aβ
plaque density were measured as being associated with
network dynamics, a distinct impact of ApoE-ε4 on net-
work expression was observable, suggesting an association
with an increased risk for AD. Moreover, cerebral iron
Fig. 4 Group differences between subjects with lower memory performance after 2 years and subjects without decline at follow-up, as measured
by VLMT delayed recall, in iron load of significant nodes in the anterior-posterior network (MANOVA, p < 0.05 after correction for multiple testing
by FDR). Indicated is the susceptibility measure, as a quantitative susceptibility mapping (QSM)-derived inference on local iron content. Numbers
refer to the effect size, as calculated by Cohen’s d
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accumulation may reflect pathological processes impli-
cated in AD [81, 83–85], and local interactions of accu-
mulated iron have been suggested previously to promote
neuronal damage in the context of AD [6, 7, 85–88].
These earlier considerations on interactions between iron
and AD pathology may be consistent with our lack of
identifying significant associations between local iron and
network-dynamics, when iron was corrected for Aβ.
While our data indicate memory decline within the nor-
mal range as a potential correlate of altered dynamic net-
work connectivity and increased genetic risk for AD, our
findings might furthermore support earlier considerations
on the relevance of pathological processes reflected by
local iron, such as oxidative stress, free radical activity,
and mitochondrial dysfunction [83, 84]. These processes
may be reflected by functional changes, primarily affecting
brain regions with high metabolic activity and increased
susceptibility to age-related damage [89]. Considering
these pathological processes as secondary to the earlier
manifestation of AD pathology, they nevertheless may
substantially contribute to cognitive decline [4, 81, 90, 91]
and may thus represent a correlate of the well-
established phenomenon of functional disconnection in
AD [39, 50, 89]. This interpretation may be consistent
with previous considerations on a stronger association
of functional impairment with secondary pathological
processes than with Aβ plaque density itself [92, 93].
The following limitations have to be allowed for when
appraising our reported findings. While neuropsycho-
logical performance was assessed based on measures
within 2 years, neuroimaging was performed only once
and thus only confers cross-sectional information. Add-
itional longitudinal studies are necessary to investigate
the temporal relationship of the different constituents of
pathological burden, which included Aβ plaque density
and iron load in the current study. As the number of
study participants affected by cognitive decline, and thus
power to identify functional correlates of low perform-
ance, varied between the domains investigated, negative
findings for language capacity, working memory, and ex-
ecutive function need to be interpreted with caution.
Moreover, while MRI at ultra-high field strength may
Fig. 5 Axial, sagittal and coronal views of the 2% strongest connections in brain space of a global, fronto-temporal, and fronto-occipital network (rows
1–3, respectively), demonstrated to drive the group difference between subjects who display both APOE-e4 expression and memory decline versus
the remaining sample. Brain regions are shown as nodes (spheres) where their size represents their degree and the color code matches the algebraic
sign of relative node strength (red and yellow for positive, green, turquoise and blue for negative). Connections follow the same color scheme
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provide advantages in SNR and thus facilitate detection
of pathological change [28], reproducibility of findings
may be difficult as it requires the implementation of
sequences that were originally performed on 7T on more
readily available clinical scanners with lower field
strength.
Conclusions
While the association between memory decline in the
elderly and emerging AD-related pathology is well estab-
lished, our findings suggest that variation in the subclinical
range of memory performance may be linked to alter-
ations in functional network dynamics. Moreover, our data
suggest that altered network dynamics reflect regional
pathological burden, as characterized by increased iron
accumulation, and also genetic risk, as conferred by
ApoE-ε4. Additional studies are necessary to clarify
whether the observed dynamic functional changes reflect
impaired neural integrity and thus possibly a symptom-
free stage of incipient cognitive disorder, or alternatively
may represent adaptive mechanisms activated for main-
tenance of brain functionality during aging.
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